AUKELSO

LaunchmAb

denosumab-kyqq

Biocon
BLAINJECTIONINJECTABLE
Approved
Sep 2025
Lifecycle
Launch
Competitive Pressure
30/100

Mechanism of Action

RANK Ligand Blocking Activity

Pharmacologic Class:

RANK Ligand Inhibitor

Indications (9)

postmenopausal women with osteoporosis at high risk for fracturedefinedmultiple risk factors for fractureglucocorticoid-induced osteoporosis in menwomen at high risk of fracturecontinuing systemic glucocorticoids in a daily dosage equivalent to 7osteoporosisprostate cancerbreast cancer
Company
B
Biocon
India - Bangalore
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers